Will the Price of Mounjaro Go Down in the UK?

What the September 2025 price rise tells us about where things stand

When Eli Lilly revised its UK list pricing in September 2025, the market followed quickly. Providers who had been charging closer to £120–£150 per pen at the higher doses found themselves working from a list price that had more than doubled for the 15mg pen. As widely reported at the time, this was a deliberate commercial decision by Lilly, not a supply shortage or an error. The NICE technology appraisal for tirzepatide (TA1026) had been published in December 2024, cementing its clinical standing, and that kind of regulatory endorsement typically gives a manufacturer less reason, not more, to reduce its pricing.

For a medicine that is still under patent protection and carries a Black Triangle designation on the NHS medicines page (meaning it is still under additional MHRA monitoring) there is no near-term route to generic versions. Patents on the tirzepatide molecule and its delivery system run well into the 2030s. That is the single largest factor in any honest assessment of whether the cost of Mounjaro will go down. It probably won't, materially, until those patents expire.

There is one practical habit worth building: check the GPhC pharmacy register before committing to any provider. You can verify a UK online pharmacy in under a minute at pharmacyregulation.org/registers. If a price looks far below the current market range, that register check matters more than the saving.

Could NHS commissioning push private prices down?

In theory, large-scale NHS prescribing would give Lilly an incentive to negotiate a lower NHS price, and that negotiated price would exist alongside the private list price, not replace it. NHS England's phased rollout of tirzepatide through primary care is underway, with eligibility expanding gradually through 2026 and 2027. You can read more about how that rollout is structured on our Mounjaro treatment overview page. But NHS commissioning volume typically leads to separate confidential rebate arrangements with NICE and NHS England, not a public list-price reduction that flows through to private providers. The two pricing tracks run in parallel.

What NHS expansion does change is demand. As more people become eligible for NHS tirzepatide, the pool of private patients who genuinely cannot access it on the NHS will shrink. Some providers may respond to reduced private demand by adjusting prices, and we have looked at the question of a Mounjaro price decrease and what would realistically need to happen for one to occur. Anyone hoping to wait for a price drop before starting treatment is, in effect, betting on a timeline that no one can currently quote with confidence. There is a fuller look at the timing question if that is what you are weighing up.

What headline prices often leave out

A number quoted on a comparison site or social media post is rarely the full cost of a course of treatment. Consultation fees, prescription charges, delivery costs and dose-review support are commonly billed separately by providers who advertise a lower headline figure. Some charge per appointment; some charge again when you move from one dose to the next; some charge for the delivery that feels like it should be included. These additions can close a gap that looks wide at first glance.

At nume, the price covers the consultation, the prescription, the medicine, next-working-day DPD delivery, and aftercare seven days a week. There are no subscriptions and no auto-renewals, every repeat order is clinically re-reviewed before it goes out. We are not the cheapest provider in the market, and that is a deliberate position. Our full current pricing is shown on the treatment page, alongside the consultation process. A breakdown of what is typically included (and what is not) in the wider market is covered in more detail on our Mounjaro price page.

Why 'cheapest' is the wrong test for a prescription medicine

Price is a reasonable thing to think about. It is not, though, the right primary test for a medicine that carries real clinical implications. Mounjaro requires a prescriber to assess your health history, current medicines and BMI before a prescription can be issued. The MHRA has warned publicly about counterfeit pens being sold online, some containing insulin rather than tirzepatide. Large seizures of fake pens have already taken place in the UK, and the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk exists partly to capture reports of suspect products. A small saving on the pen is not worth the risk of receiving something that was never manufactured by Eli Lilly.

The right questions to ask of any provider are whether they hold a GPhC pharmacy registration, whether a named prescriber reviews every consultation, and whether your identity and weight are verified before treatment is dispensed. Those things cost something to do properly. That cost is built into a legitimate price, which is why a price that looks dramatically lower than the market range is a signal to slow down, not speed up. If you are thinking about whether the price picture will look different further ahead, we have covered whether the price of Mounjaro is likely to go down in 2025 and also looked separately at whether the price of Mounjaro might go down in 2026. You can explore what the treatment involves further on our weight-loss treatment overview, or go straight to the free consultation.